exits

Celebrity real estate agent Chrishell Stause is moving on from Netflix’s “Selling Sunset” after nine seasons on the hit reality TV series.

Stause revealed to Bustle in a story published Friday that she is quitting the popular show, telling the outlet that not even “Jesus Christ himself” or the show’s producing team could persuade her to return. “I’ve gotten to a place where I don’t need the show financially,” the 44-year-old reality star and former “All My Children” actor told Bustle.

“I’m lucky to have other forms of employment, because it’s no longer good for my mental health,” she said.

“Selling Sunset” debuted on Netflix in 2019 and stars the female agents, including Stause, at the Sunset Strip office of the Oppenheim Group, a luxury real estate agency. Over the years, with Stause part of the main cast, the series has documented some of her professional wins and losses as well as her personal struggles, notably her divorce from “This Is Us” actor Justin Hartley in 2019. That divorce was finalized in 2021 and Stause has since remarried to Australian musician G Flip.

As Stause announced her exit to Bustle, she discussed her issues with other members of the “Selling Sunset” circle, namely co-star Emma Hernan and her boyfriend, Blake Davis. She also expressed disapproval with the series’ editing. Netflix did not comment to Bustle about Stause’s comments, but she wished the “Selling” franchise well in its future installments.

“I have no ill will toward the show. The show has given me so many opportunities, and I don’t want to be bitter about it, even though I’m leaving not in the way that I would’ve loved,” she said.

Stause, who appeared earlier this year in NBC’s celebrity competition show “The Traitors,” also talked about growing her family with G Flip and diversifying her friend groups: “I just really love being around accepting, beautiful-hearted people.”

The actor-reality star closes her “Selling Sunset” chapter two days after Netflix aired its Season 9 reunion episode. On Instagram, Stause acknowledged that “the season ended on a bit of a sour note,” but expressed gratitude to the Netflix series and its fans.

“It introduced me to you guys — and I am deeply thankful for your support. There were lots of fun memories I am going to focus on from here on out and you will see me again so it’s not goodbye,” she said Friday in an Instagram story. “Just goodbye for now.”

Florida-based wealth advisory J. L. Bainbridge & Co. sold 119,376 shares of Biogen (BIIB 0.58%) during the third quarter for an estimated $16.1 million.

What Happened

In a quarterly disclosure filed with the Securities and Exchange Commission on Friday, J. L. Bainbridge & Co. Inc. reported selling 119,376 shares of Biogen (BIIB 0.58%) during the third quarter. The estimated value of the shares sold was $16.1 million, based on the average closing price for the period. The fund now holds just 2,969 shares of Biogen valued at $415,898 as of September 30.

What Else to Know

The sale reduced Biogen to 0.03% of reported U.S. equity assets under management as of September 30.

Top holdings after the filing:

• NASDAQ:MSFT: $164.85 million (13.9% of AUM)
• NASDAQ:AAPL: $122.68 million (10.4% of AUM)
• NASDAQ:GOOGL: $116.65 million (9.9% of AUM)
• NYSE:GS: $71.43 million (6% of AUM)
• NYSE:ETN: $59.86 million (5.1% of AUM)

As of Friday’s market close, shares of Biogen were priced at $143, down 23% over the past year.

Company Overview

Company Snapshot

• Biogen’s portfolio includes therapies for neurological and neurodegenerative diseases, such as multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, and biosimilars targeting autoimmune disorders.
• The company generates revenue through the discovery, development, manufacturing, and commercialization of branded pharmaceuticals and biosimilars, with a focus on specialty and rare disease markets.
• Biogen serves a global customer base, including healthcare providers, hospitals, and specialty pharmacies treating patients with neurological and rare diseases.

Biogen specializes in therapies for complex neurological and neurodegenerative conditions. With a diversified product suite and a robust pipeline, Biogen leverages scientific innovation and strategic collaborations to maintain its position in high-need therapeutic areas.

Foolish Take

Florida-based J.L. Bainbridge & Co. dramatically scaled back its Biogen holdings last quarter, selling nearly its entire position for roughly $16 million. The firm, known for its long-term focus and balanced growth strategy, now holds only about $416,000 worth of Biogen stock—just 0.03% of its reportable U.S. equity assets.

The timing aligns with Biogen’s mixed performance over the past year. Shares are down 23%, despite a strong second-quarter report showing 7% year-over-year revenue growth to $2.6 billion and raised full-year guidance. The company highlighted sequential growth in Alzheimer’s therapy LEQEMBI, rare-disease drug SKYCLARYS, and postpartum-depression treatment ZURZUVAE, with CEO Christopher Viehbacher calling it “another quarter of strong execution” as Biogen reshapes its portfolio for sustainable growth. Still, the stock has struggled amid investor skepticism fueled by declining sales.

Bainbridge’s near-exit follows other portfolio adjustments—such as trims to Delta Air Lines—as the firm concentrates its holdings in proven large-cap growth names like Microsoft, Apple, and Alphabet. For long-term investors, Biogen’s upcoming October 30 earnings will be a key moment to gauge whether its new drug launches can meaningfully offset the erosion of its older franchises.

Glossary

AUM (Assets Under Management): The total market value of assets a fund or investment manager oversees on behalf of clients.
Quarterly disclosure: A report filed every three months detailing a fund’s holdings, transactions, and other relevant financial information.
Post-trade stake: The number of shares or percentage of ownership remaining after a buy or sell transaction.
Top holdings: The largest investments in a fund’s portfolio, usually ranked by market value or portfolio percentage.
Biosimilars: Biologic medical products highly similar to already approved reference drugs, used to treat various diseases.
Specialty and rare disease markets: Healthcare sectors focused on developing treatments for uncommon or complex medical conditions.
Pipeline: The portfolio of drugs or products a company is developing, from early research to late-stage clinical trials.
Strategic collaborations: Partnerships between companies to jointly develop, market, or distribute products or technologies.
TTM: The 12-month period ending with the most recent quarterly report.

Strictly Come Dancing’s Karen Carney has shared her heartbreak after another star was booted off the series

After performing a Thunderbirds themed routine for Movie Week, Ross King became the second celebrity to be eliminated from Strictly Come Dancing.

He failed to impress the judges as he faced Balvinder Sopal in the dreaded dance-off.

Fellow Strictly Come Dancing star Karen Carney took to Instagram to share their heartache over Ross’ exit.

Alongside a snap of her with Ross in their Movie Week outfits, Karen penned: “Absolutely gutted. Since the beginning of this show @therossking has been a rock for me and is one of the most genuine and funny people I’ve ever met.

“Have loved every minute of our @bbcstrictly journey and will miss you loads but know I’ll have a mate for life.”

Speaking on the Strictly results show, Ross said about his time on the show: “I have loved every single minute of it.

“I would like to say thank you to everyone who has supported us, all the people who voted – they’ve been amazing.

“I want to thank everyone here in this room, backstage, the judges, the crew – every single person here has made me so, so welcome.

“And, I want to thank a very special lady who has been with me through it all and has been absolutely everything: she’s been a mentor, teacher, carer and I could not have wished for a better partner, and I could not have wished to be on a better show. Thank you judges for all your remarks.”

Meanwhile, Jowita shared: “Thank you so much for all of your work. For everything you have done during rehearsals.

“We laugh a lot – but we also cried! Thank you so much, and I hope I’m going to be a little part in your life forever.”

Both Jowita and Ross will appear on It Takes Two on Monday in their first TV interview after their elimination.

Ross also shared a number of snaps from his time on the show on Instagram as he reflected on his journey.

Strictly Come Dancing returns on Saturday 18 October at 6:30pm, with the results show on Sunday 19 October at 7:15pm on BBC One and BBC iPlayer